DOCSLIB.ORG

Catheterization Lab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Catheterization Lab Recommendations for Anticoagulation Therapies Anticoagulation and Thrombophilia Clinic 800 East 28th Street, Minneapolis, MN 55407 612-863-6800 allinahealth.org/mhi | mplsheart.com AKN S414386 281375 Table of Contents Recommendations for Anticoagulation Therapies Direct Oral Anticoagulants (DOACs) Guide .............................................................................................................................. 3–14 Management of Bleeding Associated with Direct Oral Anticoagulants (DOACs) ................................................................... 15–25 Switching To and From Anticoagulants .................................................................................................................................. 26–32 Management of Periprocedural Anticoagulation ..................................................................................................................... 33-50 Warfarin ................................................................................................................................................................. 34 DOACs ...............................................................................................................................................................35-37 Bleeding Risks ........................................................................................................................................................ 38 Thrombotic Risks ................................................................................................................................................... 39 Cardiac Electrophysiology ..................................................................................................................................40-44 Cardiac Catheterization Lab ............................................................................................................................. 45-46 Neuraxial Access or Peripheral Nerve Procedures ................................................................................ 47-50 DVT and PE Prophylaxis in Medically Ill Patients ..........................................................................................................................51-61 Thromboprophylaxis for Congenital Heart Patients ......................................................................................................................61-62 DVT and PE Anticoagulation Management Recommendations ....................................................................................................63-69 Thrombophilia Work-up Recommendations ..................................................................................................................................70-79 Watchman (Left Atrial Appendage Occluder Device) Non-Implanter Reference ............................................................................80-82 Access the most recent version online on the AKN at Abbott Northwestern Hospital > Excellian patient care quick links. Anticoagulation and Thrombophilia Clinic 800 East 28th Street, Minneapolis, MN 55407 612-863-6800 | Reviewed August 2016, June 2018, July 2019 allinahealth.org/mhi | mplsheart.com Direct Oral Anticoagulants (DOACs) Guide Anticoagulation and Thrombophilia Clinic, Minneapolis Heart Institute®, Abbott Northwestern Hospital. Tel: 612-863-6800 S414386A 281375 0517 ©2017 ALLINA HEALTH SYSTEM. TM A TRADEMARK OF ALLINA HEALTH SYSTEM. MINNEAPOLIS HEART INSTITUTE® AND MHI® ARE TRADEMARKS OF MINNEAPOLIS HEART INSTITUTE®, INC. 3 Direct Oral Anticoagulants (DOACs) Guide Direct Thrombin Direct Factor Xa Inhibitors (Factor IIa) Inhibitor apixaban edoxaban rivaroxaban betrixaban dabigatran (Pradaxa®) (Eliquis®) (Savaysa®) (Xarelto®) (Byvexxa®) NVAF NVAF NVAF Prophylaxis of VTE in NVAF FDA Approved 5 mg PO BID CrCl > 95 mL/min: CrCl > 50 mL/min: 20 mg adults hospitalized for CrCl >30 mL/min: 150 Indications and 2.5 mg PO BID: If ≥ 2 of NOT recommended PO daily with evening meal acute medical illness mg PO BID Dosage the following: age ≥80 (drug may be cleared CrCl ≤ 50 mL/min: 15 mg with moderate or CrCl 15-30 mL/min: 75 years, weight ≤60 kg or too rapidly and PO daily with evening meal severe restricted mg PO BID Cr ≥ 1.5 mg/dL adequate drug levels mobility CrCl < 15 mL/min: not not attained) VTE treatment 160 mg PO initial recommended Usage if Cr > 2.5 mg/dL CrCl ≥30 mL/min: CrCl 51-95 mL/min: single dose, or CrCl < 25 mL/min is 15 mg PO BID for 21 days, VTE treatment and 60 mg PO once daily followed by 80 mg based on then 20 mg PO daily secondary prevention pharmacokinetics and CrCl 15-50 mL/min: same time daily For VTE treatment, an CrCl < 30 mL/min: not on clinical studies. 30 mg PO once daily with food for 35 to initial 5-10 days of Caution is advised. not recommended 42 days CrCl < 15 mL/min: not parenteral CrCl 15-29 mL/min: VTE treatment recommended VTE secondary prevention anticoagulation is 80 mg PO initial 10 mg PO BID for 7 days, CrCl ≥ 30 mL/min: required before VTE treatment single dose, initiating dabigatran then 5 mg PO BID 10 mg PO daily, with or Begin after 5-10 days followed by 40 mg CrCl >30 mL/min: 150 No dose adjustment without food, after at least of initial therapy with a same time daily mg PO BID based on renal function 6 months of standard parenteral with food for 35 to CrCl ≤30 mL/min: not Usage if CrCl < 25 treatment. anticoagulant 42 days recommended mL/min is based on CrCl > 50 mL/min: 60 CrCl < 30 mL/min: CrCl < 15 mL/min: pharmacokinetics and not mg PO once daily not recommended not recommended VTE prophylaxis in THR CrCl >30 mL/min: 110 on clinical studies. CrCl 15-50 mL/min or With concomitant Caution is advised. VTE prophylaxis in THR/TKR mg for the first day, then weight ≤60 kg or on P- Start 6-10 hours post-op use of P-gp gp inhibitor§: 30 mg PO inhibitor§: 80 mg PO 220 mg PO daily VTE secondary prevention THR: 10 mg PO daily for once daily initial single dose, CrCl ≤30 mL/min or on 2.5 mg PO BID 35 days followed by 40 mg dialysis: dosing CrCl < 25 mL/min: no VTE secondary TKR: 10 mg PO daily for same time daily recommendations not clinical studies prevention 12 days with food for 35 to available VTE prophylaxis in Not approved Avoid if CrCl < 30 mL/min 42 days CrCl <50 mL/min with THR/TKR VTE prophylaxis in concomitant use of P-gp Start 12-24 hours postop § THR/TKR Reduction of Risk of Major inhibitor : avoid co- THR: 2.5 mg BID PO for Not approved Cardiovascular Events administration 35 days Chronic CAD and/or PAD: VTE prophylaxis in TKR TKR: 2.5 mg BID PO for 2.5 mg PO BID in Not approved 12 days combination with aspirin CrCl < 30 mL/min: no 81 mg PO daily clinical studies 4 Direct Oral Anticoagulants (DOACs) Guide Direct Thrombin Direct Factor Xa Inhibitors (Factor IIa) Inhibitor apixaban edoxaban rivaroxaban betrixaban dabigatran (Pradaxa®) (Eliquis®) (Savaysa®) (Xarelto®) (Byvexxa®) Capsules: 75 mg, 110 mg, 150 mg Keep in original container; remove only at time of use. Close bottle immediately Tablets: 15 mg, 30 mg, Tablets: 2.5 mg, 10 mg, 15 mg, Tablets: 2.5 mg, 5 mg Capsules: 40 mg, 80 mg after use. Keep tightly Dosage Forms 60 mg 20 mg closed. Do not put in pillbox or medication organizer. Use within 4 months after opening bottle. Yes No data are available Yes May dissolve in No water or apple juice, Both 2.5 mg and 5 regarding The 15 mg and 20 mg Do not chew, break, or or mix with mg tablets may be bioavailability upon tablets may be crushed open capsules applesauce. For crushed and crushing and/or and mixed with (bioavailability increases by administration by suspended in 60 mL mixing edoxaban applesauce for oral use 75% if capsule is opened) NG or feeding tube, D5W and tablets into food, or with 50 mL of water Able to Crush liquids, or dissolve in water. Medication immediately for NG or gastric tube delivered through an administration feeding (avoid if distal to After NGT through feeding the stomach). After administration, oral tubes. or enteral feeding No information available administration, oral or should immediately regarding oral enteral feeding should follow the dose. administration of immediately follow the crushed and suspended dose. tablets 20 mg: with food Administration with 15 mg: with food With or without food With or without food With food With or without food food 2.5 mg,10 mg: with or without food Half-life 8-15 hours 10-14 hours 5-13 hours 19-27 hours 12-17 hours T-max 3-4 hours 1-2 hours 2-4 hours 3-4 hours 1-3 hours Renal 27% Renal 50% Renal 50% Feces: 85% Renal 80% Hepatic unchanged drug Metabolism Hepatic 73% Metabolism, biliary/intestinal 50% 1/3 eliminated non- Renal: 11-18% metabolized 5 Direct Oral Anticoagulants (DOACs) Guide Direct Thrombin Direct Factor Xa Inhibitors (Factor IIa) Inhibitor apixaban edoxaban rivaroxaban betrixaban dabigatran (Pradaxa®) (Eliquis®) (Savaysa®) (Xarelto®) (Byvexxa®) Bleeding Bleeding Bleeding Bleeding Bleeding Thrombocytopenia GI: dyspepsia, abdominal Thrombocytopenia Hypokalemia Abnormal LFTs Hypersensitivity and epigastric pain reaction Side Effects Hypersensitivity reaction Rash Hypertension GI bleed Stevens-Johnson Thrombocytopenia Headache Anemia Syndrome Hypersensitivity reaction Agranulocytosis Hypersensitivity Hepatitis reaction Not studied and Not studied and Not studied and should No data in pregnancy Not studied and should be should be avoided should be avoided be avoided but treatment likely to avoided increase risk of Lactation: not Lactation: not
Load more

Recommended publications
  • Extended-Duration Betrixaban Versus Shorter-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Critically Ill Medical
    Intensive Care Med (2019) 45:477–487 https://doi.org/10.1007/s00134-019-05565-6 ORIGINAL Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy Gerald Chi1* , C. Michael Gibson2, Arzu Kalayci1, Alexander T. Cohen3, Adrian F. Hernandez4, Russell D. Hull5, Farima Kahe1, Mehrian Jafarizade1, Sadaf Sharfaei1, Yuyin Liu6, Robert A. Harrington7 and Samuel Z. Goldhaber8 © 2019 Springer-Verlag GmbH Germany, part of Springer Nature Abstract Purpose: To assess the efcacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among criti- cally ill patients. Methods: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35–42 days or enoxa- parin for 10 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and± 547 patients who had no severe renal insufciency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical beneft (composite of VTE and major bleeding), and mortality was compared at 35–42 days and at 77 days. Results: At 35–42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P 0.042) without causing excess major bleeding (1.14% vs 3.13%, P 0.07). Both VTE (3.32% vs 8.33%, P 0.013) and= major bleeding (0.00% vs 3.26%, P 0.003) were decreased in the full-dose= stratum. Patients who received= betrixaban had more non-major bleeding= than enoxaparin (overall population: 2.56% vs 0.28%, P 0.011; full-dose stratum: 3.32% vs 0.36%, P 0.010).
    [Show full text]
  • Standard-Dose Apixaban After Very Low-Dose Thrombolysis for Acute Intermediate-High Risk Acute Pulmonary Embolism
    SAFE-LYSE | STUDY PROTOCOL Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis Title: for Acute Intermediate-high Risk Acute Pulmonary Embolism Short Title: SAFE-LYSE Protocol Version: Issue Date: 28/AUG/2019 Principal Victor Tapson1,2, Aaron Weinberg1,2 Investigators: Sub Investigators: Sam Torbati1, Susan Jackman1, Niree Hindoyan1, Joseph Meza1 1Cedars-Sinai Medical Center 8700 Beverly Blvd Los Angeles, CA 90048 Affiliations: 2Cedars-Sinai Medical GrouP 200 N. Robertson Blvd. Beverly Hills, CA 90211 Victor TaPson 8730 Alden Drive, W155 Primary Contact: Los Angeles, CA 90048 (919) 971-6441 Investigator-Initiated Bristol-Myers Squibb Company (BMS) Study Funded By: Version 8.0 | Date: 28Aug2019 1 SAFE-LYSE | STUDY PROTOCOL STUDY SYNOPSIS Funding Provided by BMS/Pfizer Alliance Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Protocol Title Acute Intermediate-high Risk Acute Pulmonary Embolism (SAFE-LYSE) Pulmonary embolism (PE) is a major cause of mortality in the United States, with an estimated 100,000 deaths annually and uP to 30% of Patients dying within the first month of diagnosis. Recent guidelines now risk-stratify intermediate-risk PE Patients to intermediate-low and intermediate-high risk categories, but consensus on treatment for those Patients are controversial, as compared to that of high or low-risk Patients. Because of an increased risk of major, non-major, and intracranial bleeding and an uncertain effect on survival and Post-thrombotic complications, thrombolysis is not routinely recommended in the guidelines for intermediate- risk Patients. However, studies have evaluated half-dose (50 mg dose) tissue Plasminogen activator (tPA) and this aPPears to be effective for treating PE with a reduced yet still significant risk of bleeding.
    [Show full text]
  • 201370Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201370Orig1s000 MEDICAL REVIEW(S) M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH Date: July 8, 2011 From: Kathy M. Robie-Suh, M.D., Ph.D. Medical Team Leader Division of Hematology Products Subject: NDA 201370, resubmission April 11, 2011 Heparin Sodium Injection (heparin sodium, USP) Sponsor: Pfizer, Inc. 235 East 42nd Street New York, NY 10017-5755 To: NDA 201370 This is the second review cycle for this 505(b)(2) application for a new Heparin Sodium Injection product derived from porcine intestine. The presentations include several containing benzyl alcohol as a preservative and one preservative-free presentation. The first cycle review of the NDA found the application acceptable from a clinical viewpoint. However, manufacturing facilities inspection identified deficiencies that precluded approval and a Complete Response (CR) letter was issued on April 7, 2011. Labeling review was not completed at that time. In the current resubmission the sponsor has responded to the identified deficiencies deleting the two heparin supplier sites where deficiencies were found. The Amended Cross-Discipline Team Leader Review by Dr. Ali Al-Hakim (6/28/2011) comments that Office of Compliance has updated its recommendation in the Establishment Evaluation System and issued “ACCEPTABLE” overall recommendation for this NDA on June 27, 2011 and therefore the NDA is recommended for approval. No new clinical information is included in the resubmission. Clinical review of the original application and the resubmission was conducted by Dr.
    [Show full text]
  • Laboratory Monitoring of Direct Oral Anticoagulants (Doacs)
    biomedicines Review Laboratory Monitoring of Direct Oral Anticoagulants (DOACs) Claire Dunois HYPHEN BioMed, Sysmex Group, 95000 Neuville sur Oise, France; [email protected] Abstract: The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies. DOACs directly, selectively, and reversibly inhibit factors IIa or Xa. The coagulation effect follows the plasma concentration–time profile of the respective anticoagulant. The short half-life of a DOAC constrains the daily oral intake. Because DOACs have predictable pharmacokinetic and pharmacodynamic responses at a fixed dose, they do not require monitoring. However in specific clinical situations and for particular patient populations, testing may be helpful for patient management. The effect of DOACs on the screening coagulation assays such as prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) is directly linked to reagent composition, and clotting time can be different from reagent to reagent, depending on the DOAC’s reagent sensitivity. Liquid chromatography–mass spectrometry (LC-MS/MS) is considered the gold standard method for DOAC measurement, but it is time consuming and requires expensive equipment. The general consensus for the assessment of a DOAC is clotting or chromogenic assays using specific standard calibrators and controls. This review provides a short summary of DOAC properties and an update on laboratory methods for measuring DOACs. Keywords: DOAC; monitoring; screening assays; quantitative assays Citation: Dunois, C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). 1. Introduction Biomedicines 2021, 9, 445. https:// Direct oral anticoagulants (DOACs) constitute first-line therapy used for many throm- doi.org/10.3390/biomedicines9050445 boembolic indications, such as prevention and treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF) [1,2].
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • The Role of Direct Oral Anticoagulants in the Management of Venous Thromboembolism Taylor Steuber, Pharmd, BCPS
    REPORT The Role of Direct Oral Anticoagulants in the Management of Venous Thromboembolism Taylor Steuber, PharmD, BCPS enous thromboembolism (VTE), including deep vein ABSTRACT thrombosis (DVT) and pulmonary embolism (PE), occurs in as many as 900,00 people in the United States each Appropriate treatment of venous thromboembolism (VTE) is critical to year, with up to 100,000 Americans dying as a result.1 A minimizing long-term morbidity and mortality. The emergence of direct Vcommon complication, VTE is the most preventable cause of death oral anticoagulants (DOACs) has provided clinicians with expanded in hospitalized patients.2 Once VTE occurs, long-term mortality therapeutic options for patients with VTE, and as a result, updated practice guidelines released by the American College of Chest Physicians is poor, with 25% of patients not surviving 7 days and nearly 40% favor DOACs over traditional anticoagulants, such as warfarin. The newest 3 not surviving the first year. Furthermore, PE with or without DVT DOAC, betrixaban, received FDA approval in 2017, with an indication has been found to be an independent predictor of reduced survival for VTE prophylaxis in hospitalized adults. Additionally, results from the compared with DVT alone.3 Among those who do survive, 30% will XALIA study on the real-world outcomes of rivaroxaban are now available. experience a recurrence of VTE within 10 years.4 A reversal agent for dabigatran, idarucizumab, also received FDA approval in 2017, and other reversal agents are in development. This article Historically, the pathogenesis of VTE has been explained with will provide an overview of current VTE treatment strategies, with an the 3 components of Virchow’s triad: hypercoagulability, hemody- emphasis on the place in therapy of the DOACs.
    [Show full text]
  • Pharmacoepidemiological.Study.Protocol.. ER1379468. A.Retrospective.Cohort.Study.To.Investigate.The.Initiation. And.Persistence.Of.Dual.Antiplatelet.Treatment.After
    Pharmacoepidemiological.study.protocol.ER1379468. % . % % % % % Pharmacoepidemiological.study.protocol.. ER1379468. A.retrospective.cohort.study.to.investigate.the.initiation. and.persistence.of.dual.antiplatelet.treatment.after.. acute.coronary.syndrome.in.a.Finnish.setting.–.THALIA. % Author:(( ( ( Tuire%Prami( Protocol(number:(( %% ER1359468,%ME5CV51306( Sponsor:(( ( ( AstraZeneca%Nordic%Baltic% Protocol(version:(( ( 2.0( Protocol(date:(( ( ( 03%Jul%2014% ( . EPID%Research%Oy%. CONFIDENTIAL. % Pharmacoepidemiological.study.protocol.ER1379468... Version.2.0. 03.Jul.2014. Study Information Title% A% retrospective% cohort% study% to% investigate% the% initiation% and% persistence% of% dual% antiplatelet%treatment%after%acute%coronary%syndrome%in%a%Finnish%setting%–%THALIA% Protocol%version% ER1359468% identifier% ME5CV51306% EU%PAS%register% ENCEPP/SDPP/6161% number% Active%substance% ticagrelor%(ATC%B01AC24),%clopidogrel%(B01AC04),%prasugrel%(B01AC22)% Medicinal%product% Brilique,% Plavix,% Clopidogrel% accord,% Clopidogrel% actavis,% Clopidogrel% krka,% Clopidogrel% mylan,%Clopidogrel%orion,%Clopidogrel%teva%pharma,%Cloriocard,%Efient% Product%reference% N/A% Procedure%number% N/A% Marketing% AstraZeneca%Nordic%Baltic:%Brilique%(ticagrelor)% authorization% holder% financing%the%study% Joint%PASS% No% Research%question% To%describe%initiation%and%persistence%of%dual%antiplatelet%treatment%in%invasively%or%non5 and%objectives% invasively%treated%patients%hospitalized%for%acute%coronary%syndrome%% Country%of%study% Finland% Author% Tuire%Prami%
    [Show full text]
  • Best Evidence for Antithrombotic Agent Reversal in Bleeding
    3/16/2021 1 JAMES H. PAXTON, MD • DIRECTOR OF CLINICAL RESEARCH • DETROIT RECEIVING HOSPITAL (DRH), DEPARTMENT OF EMERGENCY MEDICINE, WAYNE STATE UNIVERSITY • ATTENDING PHYSICIAN • SINAI-GRACE HOSPITAL (SGH) • DETROIT RECEIVING HOSPITAL (DRH) 2 1 3/16/2021 DISCLOSURES • FUNDED RESEARCH SPONSORED BY: TELEFLEX INC, 410 MEDICAL, HOSPI CORP. 3 OBJECTIVES •AT THE CONCLUSION OF THIS LECTURE, THE LEARNER WILL: • RECOGNIZE COMMON ANTITHROMBOTIC MEDICATIONS ASSOCIATED WITH BLEEDING EMERGENCIES • BE ABLE TO EXPLAIN THE MECHANISMS OF ACTION FOR COMMON ANTITHROMBOTIC MEDICATIONS • UNDERSTAND THE EVIDENCE FOR RAPID REVERSAL OF ANTITHROMBOTIC MEDICATIONS, INCLUDING CONTROVERSIES AND BEST PRACTICES HAVE FEWER NIGHTMARES ABOUT SCENES LIKE THE ONE ON THE NEXT SLIDE? 4 2 3/16/2021 BLEEDING IS BAD 5 WHEN TO REVERSE? • WHEN RISK OF BLEEDING OUTWEIGHS RISK OF REVERSAL: • INTRACRANIAL HEMORRHAGE (ICH) • OTHER CNS HEMATOMA (E.G., INTRAOCULAR, SPINAL) • EXSANGUINATING GASTROINTESTINAL (GI) BLEED • UNCONTROLLED RETROPERITONEAL BLEED • HEMORRHAGE INTO EXTREMITY WITH COMPARTMENT SYNDROME • CONSIDER IN POSTERIOR EPISTAXIS, HEMOTHORAX, PERICARDIAL TAMPONADE 6 3 3/16/2021 ANTITHROMBOTIC AGENTS •ANTI-PLATELET DRUGS •ANTI-COAGULANTS •FIBRINOLYTICS 7 THROMBOGENESIS • Primary component in arterial thrombosis (“white clot”) • Target for antiplatelet drugs • Primary component in venous thrombosis (“red clot”) • Aggregated platelets + • Target for anticoagulants fibrin mesh • Target for fibrinolytics 8 4 3/16/2021 PLATELET AGGREGATION Antiplatelet Drugs Mechanism Aspirin*
    [Show full text]
  • List Item Refludan : EPAR
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures which have been finalised before 1 August 2003. For scientific information on procedures after this date please refer to module 8B. I Introduction Refludan contains Lepirudin ([Leu1-Thr2]-63-desulfohirudin) as the active substance. Lepirudin is a hirudin analogue produced in yeast cells transfected with an expression vector containing the hirudin gene. Refludan is presented as a powder to be reconstituted with water for injection or with isotonic saline for intravenous injection or infusion. It is supplied in one strength with a standardised content of 50 mg lepirudin per vial. The specific activity of lepirudin is approximately 16,000 (Antithrombin Units) ATU per mg, where one ATU is the amount of hirudin that neutralises one unit of the WHO preparation of thrombin (89/588). Lepirudin is a specific direct inhibitor of free and clot-bound thrombin and the proposed therapeutic indication is anticoagulation in adult patients with heparin-associated thrombocytopenia (HAT) type II and thromboembolic disease mandating parenteral antithrombotic therapy. HAT type II is a complication of heparin therapy, with a probable incidence of the order of 1% of heparin-treated patients. The disorder is characterised by, sometimes profouauthorisednd, thrombocytopenia and a high propensity for venous and arterial thromboembolic complications occurring during continued heparin treatment. Mortality and amputation rates of 20-30% and 10-20%, respectively, are cited in the more recent literature reviews. The chief underlying pathogenic mechanism seems to be a formation of antibodies directed mainly against a complex of heparin and Platelet Factor 4.
    [Show full text]
  • An Antidote to Factor Xa Inhibitors Direct Inhibitors of Factor Xa (Fxa) — Such As Rivaroxaban — Are a New Class of Anticoagulants but Lack Effective Antidotes
    RESEARCH HIGHLIGHTS IN BRIEF LEAD IDENTIFICATION Better HSP90 inhibitors Heat shock protein 90 (HSP90) is a potential target for cancer and protein misfolding disorders, yet current inhibitors —­ such as geldanamycin and derivatives —­ have hepatotoxicity. Based on the hypothesis that toxicity is due to a reaction of biological nucleophiles at the 19‑position of the quinone ring of geldanamycin, this study showed that introducing a substituent at this position blocks the reaction with nucleophiles while causing a conformational switch of the trans amide group into the cis form that is required for protein binding. These new compounds were less toxic to endothelial and epithelial cells, and also inhibited HSP90 in neuronal and cancer cells. ORIGINAL RESEARCH PAPER Kitson, R. R. A. et al. Synthesis of 19‑substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nature Chem. 5, 307–314 (2013) ANIMAL MODELS A speedy route to mutant mice Generating mouse models that have targeted genetic mutations currently relies on the use of targeting vectors and mutant embryonic stem cells (ESCs). Wefers et al. identified a new, quicker way of making mouse models of disease by microinjecting transcription activator-like effector nucleases (TALENs) and synthetic oligodeoxynucleotides into single-cell embryos. The authors created disease-relevant, correctable mutations in the small GTPase RAB38. This technology enabled heterozygous mutant mice to be available within 18 weeks (ESC-based mutant mice can take a year or longer to produce). ORIGINAL RESEARCH PAPER Wefers, B. et al. Direct production of mouse disease models by embyro microinjection of TALENs and oligodeoxynucleotides. Proc.
    [Show full text]
  • Betrixaban for the Prevention of Venous Thromboembolism – First Line
    Horizon Scanning Centre September 2014 Betrixaban for the prevention of venous thromboembolism – first line SUMMARY NIHR HSC ID: 4239 Betrixaban is intended to be used for the first-line prevention of venous thromboembolism (VTE) in acute medically ill patients (including one of the following: congestive heart failure, acute respiratory failure, acute infection without septic shock, acute rheumatic disorders or acute ischemic stroke with lower extremity hemiparesis or hemi paralysis) in the in-hospital and post- discharge settings. If licensed, betrixaban will offer an oral anticoagulant treatment to prevent VTE, in a patient group who do not currently have a licensed factor Xa inhibitor available, and that extends into the post This briefing is discharge period. Betrixaban is a small molecule factor Xa inhibitor which based on acts as an anticoagulant to prevent thrombosis. Factor Xa is a key information component of the coagulation pathway, directly converts prothrombin to available at the time thrombin (factor IIa), via the prothrombinase complex, which in turn converts of research and a fibrinogen to fibrin to form clots. An excess tendency to form clots is an limited literature important contributor to VTE. Betrixaban does not currently have a Marketing search. It is not Authorisation in the EU for any indication. intended to be a definitive statement VTE is a common condition which encompasses pulmonary embolism (PE) on the safety, and deep vein thrombosis (DVT). VTE has an annual incidence of efficacy or approximately 2 in 1,000 population. However, the risk of VTE varies effectiveness of the substantially with age; for people aged under 40 years incidence of VTE is 1 health technology per 10,000 population, whereas for those over 80 years, the incidence rises covered and should to 1 per 100 population.
    [Show full text]
  • Current View on Anticoagulant and Thrombolytic Treatment of Acute Pulmonary Embolism
    REVIEW ARTICLES The Russian Archives of Internal Medicine • № 5 • 2019 DOI: 10.20514/2226-6704-2019-9-5-348-366 UDC: 616.24-005.7+615.273.53 G. A. Ignatenko1, G. G. Taradin*1,2, N. T. Vatutin1,2, I. V. Kanisheva1 1 State Educational Organization of Higher Professional Education M. Gorky Donetsk National Medical University, Donetsk, Ukraine 2 State Institution V. K. Gusak Institute of Urgent and Recovery Surgery, Donetsk, 283045, Ukraine CURRENT VIEW ON ANTICOAGULANT AND THROMBOLYTIC TREATMENT OF ACUTE PULMONARY EMBOLISM Abstract The presented review concerns contemporary views on specific aspects of anticoagulant and thrombolytic treatment of venous thromboembolism and mostly of acute pulmonary embolism. Modern classifications of patients with acute pulmonary embolism, based on early mortality risk and severity of thromboembolic event, are represented. The importance of multidisciplinary approach to the management of patients with pulmonary embolism with the assistance of cardiologist, intensive care specialist, pulmonologist, thoracic and cardiovascular surgeon, aimed at the management of pulmonary embolism at all stages: from clinical suspicion to the selection and performing of any medical intervention, is emphasized. Anticoagulant treatment with the demonstration of results of major trials, devoted to efficacy and safety evaluation of anticoagulants, is highlighted in details. Moreover, characteristics, basic dosage and dosage scheme of direct (new) oral anticoagulants, including apixaban, rivaroxaban, dabigatran, edoxaban and betrixaban are described in the article. In particular, the management of patients with bleeding complications of anticoagulant treatment and its application in cancer patients, who often have venous thromboembolism, is described. Additionally, modern approaches to systemic thrombolysis with intravenous streptokinase, urokinase and tissue plasminogen activators are presented in this review.
    [Show full text]